NCT05672784

Brief Summary

Comparison of the analgesic and physical recovery effect of genicular nerve block (GNB) alone and (GNB + infiltration between popliteal artery and posterior capsule of the knee (IPACK) in patients undergoing total knee replacement

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
63

participants targeted

Target at P25-P50 for not_applicable postoperative-pain

Timeline
Completed

Started Nov 2022

Longer than P75 for not_applicable postoperative-pain

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 5, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

November 5, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

January 5, 2023

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 5, 2024

Completed
25 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2024

Completed
Last Updated

November 26, 2024

Status Verified

November 1, 2024

Enrollment Period

2.1 years

First QC Date

November 5, 2022

Last Update Submit

November 22, 2024

Conditions

Keywords

genicular ,IPACK, total knee

Outcome Measures

Primary Outcomes (7)

  • 2 hours visual analogue scale

    pain intensity at rest and with motion using visual analogue scale from " horizontal line of 10-cm long with two ends, one end indicate no pain 0 and the other end indicate worst pain 10".

    at 2 hour postoperative.

  • 4 hours visual analogue score

    pain intensity at rest and with motion using visual analogue scale from " horizontal line of 10-cm long with two ends, one end indicate no pain 0 and the other end indicate worst pain 10".

    at 4 hours postoperative

  • 6 hours visual analogue score

    pain intensity at rest and with motion using visual analogue scale from " horizontal line of 10-cm long with two ends, one end indicate no pain 0 and the other end indicate worst pain 10".

    at 6 hours postoperative

  • 8 hours visual analogue score

    pain intensity at rest and with motion using visual analogue scale from " horizontal line of 10-cm long with two ends, one end indicate no pain 0 and the other end indicate worst pain 10".

    at 8 hours postopertaive

  • 12 hours visual analogue score

    pain intensity at rest and with motion using visual analogue scale from " horizontal line of 10-cm long with two ends, one end indicate no pain 0 and the other end indicate worst pain 10".

    at 12 hours postoperative

  • 18 hours visual analogue score

    pain intensity at rest and with motion using visual analogue scale from " horizontal line of 10-cm long with two ends, one end indicate no pain 0 and the other end indicate worst pain 10".

    at 18 hours postoperative

  • 24 hours visual analogue score

    pain intensity at rest and with motion using visual analogue scale from " horizontal line of 10-cm long with two ends, one end indicate no pain 0 and the other end indicate worst pain 10".

    at 24 hours postoperative

Secondary Outcomes (7)

  • • Time of performance of block

    from putting of U.S probe till the end of block procedure

  • • Total morphine consumption

    at 24 hours post-operatively

  • •incidence of Anticipated side effect

    at 24,48 hours postoperative

  • degree of maximum active flexion and extension of the knee

    at 24 hours post operative

  • walk test

    at 24 hours post operative

  • +2 more secondary outcomes

Study Arms (3)

C group

ACTIVE COMPARATOR

the patients will take standard analgesia ( meloxicam (15 mg) once a day + paracetamol 1gm /3 times a day). ,with no nerve block

Drug: standard analgesia (paracetamol and meloxicam)

G group

ACTIVE COMPARATOR

the patients will take standard analgesia plus GNB

Procedure: GNB plus standard analgesiaDrug: standard analgesia (paracetamol and meloxicam)

GI group

ACTIVE COMPARATOR

the patients will take standard analgesia plus GNB plus IPACK

Procedure: GNB plus IPACK block plus standard analgesiaDrug: standard analgesia (paracetamol and meloxicam)

Interventions

When patients are in supine position with a pillow under the popliteal fossa, we will target points next to superior medial, superior lateral, and inferior medial genicular arteries to block the superior medial, superior lateral, and inferior medial branches of genicular nerve. For identification, we will use color Doppler near the periosteal areas (the junctions of the epicondyle with the shafts of the femur and tibia, accordingly). using a 12 MHz linear transducer (XarioTM SSA-660A, Toshiba Medical Systems Corporation, Otawara, Japan) positioned parallel to the shaft of the long bones in the legs, the needle will be inserted ( in plane technique in the long-axis view) and a 2.5 mL of bupivacaine (5%) will be injected at each target points.standard analgesia will be given post-operativelly (paracetamol 1 gm/ three times a daily and meloxicam (15 mg)once a day)

Also known as: genicular block and standard analgesia
G group

IPACK block will be done when the patients in supine position with the knee flexed in 45 degree. using a low frequency transducer at a depth of 3.5-4 cm positioned transversely, 2-3 cm above the patella and over the medial aspect of the knee, we will identify the distal part of the shaft of the femur and the popliteal artery with sliding the transducer proximally and distally (If the two femoral condyles appear first, proximal sliding of the probe, so the humps of the femoral condyles will disappeared and the flat metaphysis will appeared). With advancement of the needle in plane toward the space between the popliteal artery and the femur, 15 ml of bupivacaine 0.5% will be injected. The genicular nerve block will be done as in group G and standard analgesia will be given post-operative as in group G

Also known as: genicular bock and IPACK block and standard analgesia
GI group

(paracetamol 1 gm 3 times a daily and meloxicam (15 mg) once aday.

Also known as: standard analgesia with no nerve block
C groupG groupGI group

Eligibility Criteria

Age21 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Adult patients aged between 21 to 60 years
  • undergoing primary unilateral elective total knee arthroplasty under spinal anesthesia
  • Having informed consents
  • patients with physical status ASA I \& II
  • both genders
  • body mass index less than 40 kg/m2.

You may not qualify if:

  • patients with Peripheral vascular disease
  • patients with history of allergy to local anesthesia or opioid analgesia,
  • those on anti-platelet, anticoagulant or B blocker drugs
  • Patients with acute decompensated heart failure
  • Patients with hypertension
  • Patients with heart block
  • Patients with coronary disease
  • Patients with bronchial asthma
  • Patients with bleeding disorders
  • Patients with compromised renal or hepatic function
  • pregnant female.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Heba M Fathi

Zagazig, Egypt

RECRUITING

Related Publications (1)

  • Fathi HM, Fahmy AM, Shaker MA, Kamel AAF. Comparison of genicular nerve block and its combination with IPACK block for analgesia and recovery after total knee arthroplasty: a randomized trial. BMC Anesthesiol. 2025 Nov 29;25(1):601. doi: 10.1186/s12871-025-03408-0.

MeSH Terms

Conditions

Pain, Postoperative

Interventions

AcetaminophenMeloxicam

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesThiazinesSulfur CompoundsThiazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Heba M Fathi, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. Heba M Fathi

Study Record Dates

First Submitted

November 5, 2022

First Posted

January 5, 2023

Study Start

November 5, 2022

Primary Completion

December 5, 2024

Study Completion

December 30, 2024

Last Updated

November 26, 2024

Record last verified: 2024-11

Locations